Supplementary Material for: Reply to the letter regarding ‘Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study’

Name: Supplementary Material for: Reply to the letter regarding ‘Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study’
Creator: Karger Publishers
Published: 2025-06-01 07:54:02
License: 暂无描述

DataCite Commons2025-06-01 更新2024-08-19 收录

下载链接：

https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Reply_to_the_letter_regarding_Impact_of_Bevacizumab_Being_Skipped_due_to_Adverse_Events_of_Special_Interest_for_Bevacizumab_in_Patients_with_Unresectable_Hepatocellular_Carcinoma_Treated_with_Atezolizumab_plus_Bev/25756893/1

下载链接

链接失效反馈

官方服务：

资源简介：

Medicine

提供机构：

Karger Publishers

创建时间：

2024-05-06